Valeant Subpoenaed: Price Hikes Bring Patient Assistance Scrutiny

With all of the hoopla on Capitol Hill over Valeant Pharmaceuticals International Inc.'s aggressive pricing practices involving drugs like Isuprel (isoprenaline) and Nitropress (sodium nitroprusside) – whose prices were hiked considerably after the company acquired the medicines from Marathon Pharmaceuticals in February – it was inevitable it wouldn't take long until federal prosecutors got involved.

With all of the hoopla on Capitol Hill over Valeant Pharmaceuticals International Inc.'s aggressive pricing practices involving drugs like Isuprel (isoprenaline) and Nitropress (sodium nitroprusside) – whose prices were hiked considerably after the company acquired the medicines from Marathon Pharmaceuticals in February – it was inevitable it wouldn't take long until federal prosecutors got involved.

And they did.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.